HUINNO (AI) — Funding, Investors & Signals 2026

HUINNO

Leading the digital healthcare market.

Founded 2014

Korea South 48 employees Series C Total: $56.80B AI, Hardware +3

HUINNO is a leading player in the digital healthcare market, specializing in developing wearable solutions for cardiac monitoring. Established in 2014, the company offers smartwatches and patches equipped with cutting-edge AI-based cloud analysis software, enabling easy and convenient diagnosis and treatment of cardiac diseases such as arrhythmia, atrial fibrillation, and hypertension. The digital healthcare startup has successfully established partnerships with Seoul National University Hospital, Korea University Hospital, and Yuhan Corp, demonstrating its strong presence in the industry. One of HUINNO's key technologies, MEMO AI, is an AI-based biosignal analysis solution renowned for its ability to analyze various biosignals with exceptional precision. With the capability to analyze ECG readings with a precision of 97% (significantly surpassing conventional algorithms), MEMO AI greatly enhances medical institutions' ability to increase diagnosis precision and improve the efficiency of medical services. The company's second technology allows for the convenient measurement and monitoring of various biosignals over extended periods, with devices equipped with ultra-low power technology ensuring extended usage without recharging. In December 2021, HUINNO secured a KRW43.50B Series C investment with participation from notable investors such as FuturePlay, Meritz Securities, NH Investment & Securities, DAOL Investment, and Yuhan Corporation. This latest investment highlights the confidence of prominent investors in HUINNO's innovative offerings and its potential for further growth and expansion. With its focus on revolutionizing the digital healthcare market and a strong track record of partnerships and investments, HUINNO positions itself as a key player in the industry.

Funding Stage	Amount	Investors	Lead Investors	Date
Series C	KRW43.50B	5	FuturePlay, Meritz Securities +3	28 Dec 2021
Series B	Undisclosed	5	FuturePlay, Smilegate Investment +3	21 Dec 2020
Series A	KRW5.00B	-		02 Mar 2020
Series A	KRW8.30B	-		16 Aug 2019
Seed Round	Undisclosed	-		27 Jun 2014

Funding Stage

Amount

Investors

Lead Investors

Date

Series C

KRW43.50B

FuturePlay, Meritz Securities +3

28 Dec 2021

Series B

Undisclosed

FuturePlay, Smilegate Investment +3

21 Dec 2020

Series A

KRW5.00B

02 Mar 2020

Series A

KRW8.30B

16 Aug 2019

Seed Round

Undisclosed

27 Jun 2014

FAQ About HUINNO

Leading the digital healthcare market.

HUINNO was founded in 2014.

HUINNO is headquartered in Korea South.

HUINNO operates in AI, Hardware, Health Care, Mobile and Machine Learning. Its work centres on digital healthcare, wearable technology, cardiac monitoring and AI-based analysis.

HUINNO has approximately 48 employees.

HUINNO has completed 5 funding rounds, raising a total of $56.80B. The latest funding stage is Series C.

Top alternatives and competitors to HUINNO include iRhythm Technologies, Inc., Biobeat, VitalConnect, Xsensio, PVmed (Perception Vision). These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

HUINNO and iRhythm Technologies, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

HUINNO

General Information

Discover More

About HUINNO

Funding Rounds & Investors (5)

HUINNO Alternatives & Competitors

FAQ About HUINNO